

Publisher: John Wiley & Sons Inc
E-ISSN: 1365-2516|24|1|e3-e5
ISSN: 1351-8216
Source: HAEMOPHILIA, Vol.24, Iss.1, 2018-01, pp. : e3-e5
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Related content




Galectin‐3: an emerging biomarker in stroke and cerebrovascular diseases
EUROPEAN JOURNAL OF NEUROLOGY, Vol. 25, Iss. 2, 2018-02 ,pp. :






The Challenges of Orphan Drugs and Orphan Diseases: Real and Imagined
CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 92, Iss. 2, 2012-08 ,pp. :